GlassScriptPhysician profile
Abraham Areephanthu
NPI 1548235757
$21,789.80
in general payments reported to CMS, 2019-2025
76 companies · $3,065 in 2025
The $3,065 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,110 · 2020: $2,809 · 2021: $3,018 · 2022: $3,323 · 2023: $3,049 · 2024: $3,416 · 2025: $3,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,510 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,509.61 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,627.21 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,884.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,524.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,388.27 | 2019-2025 | |
| Novo Nordisk INC | $1,233.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,009.55 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $827.25 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $774.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ironwood Pharmaceuticals, INC | $753.39 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $715.97 | 2019-2025 | Trintellix |
| Amgen INC. | $644.40 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $549.30 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $446.15 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $429.95 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $395.33 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Areephanthu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.